Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400209 | 1.00 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL15376731 | 0.82 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| Hydrochloric Acid SCHEMBL27801537 | 0.81 | LMNA (0.47) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11214027 | 0.81 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11405035 | 0.77 | PTGDR2 (0.36) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4896893 | 0.77 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL13428746 | 0.74 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4093324 | 0.74 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11678133 | 0.73 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL4359173 | 0.73 | LMNA (0.44) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108785305-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3620162-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | Calithera Biosciences Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-104220070-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2020-01-21 | — | — | CN | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| EP-2782570-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC (US) | 2019-09-18 | — | — | EP | disclosed |
| CN-108250008-A | 3,3,3`, 3`- tetramethyl -1,1`- spiro indan -6,6`- diol, derivatives chiral separation methods | 浙江大学 | 2018-07-06 | — | — | CN | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | SYNHALE THERAPEUTICS INC. | 2017-12-28 | — | — | US | disclosed |
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-5625058-A | ACYLATION, DEFORMYLATION AND EVAPORATION | FARMABIOS S.R.1. (IT) | 1997-04-29 | — | — | US | disclosed |
| EP-0578761-A4 | ENZYMATIC PROCESS FOR THE PRODUCTION OF CEFONICID. | SMITHKLINE BEECHAM CORP (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0578761-A1 | ENZYMATIC PROCESS FOR THE PRODUCTION OF CEFONICID | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-19 | — | — | EP | disclosed |
| WO-1992017600-A1 | ENZYMATIC PROCESS FOR THE PRODUCTION OF CEFONICID | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-15 | — | — | WO | disclosed |
| US-4346076-A | Bis-tetrazoylmethyl substituted cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| EP-0048169-A2 | Bis-tetrazoylmethyl substituted cephalosporin antibiotics, their preparation and pharmaceutical formulations containing them | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | disclosed |
| US-4183925-A | 7-Aminophenylacetamido-Δ3 -cephem antibacterial agents and method of use | PFIZER INC. (US) | 1980-01-15 | — | — | US | disclosed |
| US-4144240-A | USED FOR MODIFYING CEPHALOSPORINS | PFIZER INC. (US) | 1979-03-13 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4008227-A | ANTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | LMNA 4535/4885KMT2A 850/4885MEN1 1027/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | LMNA 4535/4885KMT2A 850/4885MEN1 1027/4885 |
| US-20170369485-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | LMNA 4535/4885KMT2A 850/4885MEN1 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.